IBI-354
- Generic Name
- IBI-354
Study of IBI354 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Phase 3
Recruiting
- Conditions
- OvarianPrimary PeritonealFallopian Tube Cancer
- Interventions
- Drug: paclitaxel/Gemcitabine/Liposomal doxorubicin
- First Posted Date
- 2025-02-19
- Last Posted Date
- 2025-04-13
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 450
- Registration Number
- NCT06834672
- Locations
- 🇨🇳
Affiliated Cancer Hospital of Chongqing University, Chongqing, Chongqing, China
A First-in-human Study of IBI354 in Subjects with Locally Advanced Unresectable or Metastatic Solid Tumors
Phase 1
Recruiting
- Conditions
- Locally Advanced Unresectable or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2022-12-05
- Last Posted Date
- 2025-03-20
- Lead Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Target Recruit Count
- 368
- Registration Number
- NCT05636215
- Locations
- 🇦🇺
Westmead Hospital, Sydney, New South Wales, Australia
🇦🇺Scientia Clinical Research Ltd, Randwick, New South Wales, Australia
🇦🇺Sunshine Coast University Private Hospital, Sunshine Coast, Queensland, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath